Ipsen SA (Ipsen) focuses on developing and commercializing innovative medicines in three key therapeutic areas: Oncology, Rare Disease, and Neuroscience. It also focuses on developing and commercializing medicines for cancer treatment, serving the healthcare industry. It products include Somatuline, Cabometyx, Onivyde, Decapeptyl, and Tazverik.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Ipsen's R&D arm focuses on developing innovative medicines that address conditions with high unmet medical needs. The company invests in both internal R&D platforms and external innovation to build a sustainable pipeline across all stages of development. Ipsen focuses on the discovery, development, and regulatory approval of new molecular entities, as well as lifecycle management of marketed products. The company prioritizes expanding its portfolio through disciplined business development, licensing, and mergers and acquisitions. Ipsen's R&D efforts are directed towards transformational science with precision, accelerating development with purpose, and bringing new medicines to areas of greatest need. The company has established numerous academic collaborations and partnerships with biotechnology companies to access new compounds and promising technologies for drug discovery. The R&D units of Ipsen include four global R&D centers located in Paris-Saclay, France; London, UK; Cambridge, US; and Shanghai, China. These units are responsible for managing the company's R&D activities, including the design and development of formulations, innovative delivery systems, and novel technologies to optimize the efficacy of active ingredients and improve patient quality of life. The company has a robust pipeline of products in various stages of development and has formed major technology alliances with academic institutions and biotechnology companies, including partnerships with Harvard Medical School, Boston Children's Hospital, and Marengo Therapeutics, among others. In FY2025, the company spent EUR754 million on its R&D activities, which as a percentage of revenue stood at 19.2%, and grew 9.8% YoY. The company has approximately 699 employees engaged in the R&D activities.